Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics reported positive topline results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR gene editing therapy targeting hereditary angioedema (HAE). The trial met its primary and all key secondary endpoints, showing an 87% reduction in attacks over six months versus placebo, with favo…